Evidence map›Paper›PMID 34255300›Full record

ReviewCardiovascular toxicology2021

Plausible Positive Effects of Statins in COVID-19 Patient.

Antonio Vitiello, Francesco Ferrara

Open access · hybridAbstract readReview
In one paragraph

Review in Cardiovascular toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Muscle pain and muscle weakness in COVID19 patients: Cross-talk with statins - Preliminary results.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Antonio VitielloClinical Pharmacologist, Pharmaceutical Department, Usl Umbria 1, A.Migliorati street, 06132, Perugia, Italy.ORCID 0000-0003-2623-166X
Francesco FerraraHospital Pharmacist Manager, Pharmaceutical Department, Usl Umbria 1, A.Migliorati street, 06132, Perugia, Italy. francesco.ferrara@uslumbria1.it.ORCID 0000-0001-9298-6783
Azienda Unità Sanitaria Locale di Ferrara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the onset of the global COVID-19 pandemic, there has been much discussion about the advantages and disadvantages of ongoing chronic drug therapies in SARS-CoV-2-positive patients. These discussions include also statins treatment. The statins are among the most widely used drugs in the global population. Statins aim to lower cholesterol, which is essential for many biological processes but can lead to heart disease if levels are too high; however, also the pleiotropic effects of statins are well known. So could the anti-inflammatory or the potential antiviral effects of statins be helpful in avoiding extreme inflammation and severity in COVID-19? To date, there are conflicting opinions on the effects of statins in the course of COVID-19 infection. The aim of this article is to describe the molecular and pharmacological basis of the pleiotropic effects of statins that could be more involved in the fight against COVID-19 infection and to investigate the current epidemiological evidence in the literature on the current and important topic.

Indexed as

COVID-19 Drug TreatmentAnimalsAnti-Inflammatory AgentsAntiviral AgentsCOVID-19HeartHeart DiseasesHost-Pathogen InteractionsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsSARS-CoV-2Treatment OutcomeAnti-Inflammatory AgentsAntiviral AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsCOVID-19Pleiotropic effectsSARS-COV-2Statins

Identifiers

PMID34255300
PMCPMC8275916
OpenAlexW3181578670

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.